[1] 南月敏,李佳峥.肝硬化与感染.实用肝脏病杂志,2022,25(5):609-611. [2] Conn H O.Spontaneous peritonitis and bacteremia in laennec's cirrhosis caused by entericorganisms. A relatively common but rarely recognized syndrome.Ann Intern Med,1964, 60:568-580. [3] Soriano G, Castellote J, Alvarez C, et al.Secondary bacterial peritonitis in cirrhosis: A retrospective study of clinical and analytical characteristics, diagnosis and management.J Hepatol,2010, 52(1):39-44. [4] 徐小元,丁惠国,李文刚,等.肝硬化腹水及相关并发症的诊疗指南.中华肝脏病杂志,2017,25(9):664-677. [5] Easl clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol,2010, 53(3):397-417. [6] Montano-Loza A J, Angulo P, Meza-Junco J, et al.Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.J Cachexia Sarcop Musc,2016, 7(2):126-135. [7] Montano-Loza A J, Duarte-Rojo A, Meza-Junco J, et al.Inclusion of sarcopenia within meld (meld-sarcopenia) and the prediction of mortality in patients with cirrhosis.Clin Transl Gastroenterol,2015, 6(7):e102. [8] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南.中华肝脏病杂志,2019,35(11):846-865. [9] Kong M, Geng N, Zhou Y, et al.Defining reference values for low skeletal muscle index at the l3 vertebra level based on computed tomography in healthy adults: A multicentre study.Clin Nutr,2022, 41(2):396-404. [10] Carey E J, Lai J C, Wang C W, et al.A multicenter study to define sarcopenia in patientswith end-stage liver disease.Liver Transpl,2017, 23(5):625-633. [11] Ebadi M, Tandon P, Moctezuma-Velazquez C, et al.Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.J Hepatol,2018, 69(3):608-616. [12] Cruz-Jentoft A J,Sayer A A.Sarcopenia.Lancet (London, England),2019, 393(10191):2636-2646. [13] Alberino F, Gatta A, Amodio P, et al.Nutrition and survival in patients with liver cirrhosis.Nutrition,2001, 17(6):445-450. [14] Blaak E.Gender differences in fat metabolism.Curr Opin Clin Nutr Metab Care,2001, 4(6):499-502. [15] Tandon P, Montano-Loza A J, Lai J C, et al.Sarcopenia and frailty in decompensated cirrhosis.J Hepatol,2021, 75 (Suppl 1):147-162. [16] Topan M M, Sporea I, Dănilă M, et al.Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis.Front Nutr,2021, 8:451-453. [17] Pascual-Fernández J, Fernández-Montero A, Córdova-Martínez A, et al.Sarcopenia: Molecular pathways and potential targets for intervention.Int J Mol Sci,2020, 21(22):234-238. [18] Cruz-Jentoft A J, Bahat G, Bauer J, et al.Sarcopenia: RevisedEuropean consensus on definition and diagnosis.Age Ageing,2019, 48(1):16-31. [19] Wang C W, Feng S, Covinsky K E, et al.A comparison of musclefunction, mass, and quality in liver transplant candidates: Results from the functional assessment in liver transplantation study.Transplantation,2016, 100(8):1692-1698. [20] Fujiwara N, Nakagawa H, Kudo Y, et al.Sarcopenia, intramuscular fat deposition,and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.J Hepatol,2015, 63(1):131-140. [21] Huguet A, Latournerie M, Debry P H, et al.The psoas muscle transversal diameter predicts mortality in patients with cirrhosis on a waiting list for liver transplantation: A retrospective cohort study.Nutrition,2018, (51-52):73-79. |